Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational,Post-authorization Prospective Study to Develop and Validate a Prognostic Tool for Optimizing Therapy in Patients With Hepatitis C Virus (HCV) Genotype 1 and 4.

NCT01884402 is registered in ClinicalTrials.gov with Fundación Pública Andaluza para la gestión de la Investigación en Sevilla as lead sponsor.

NCT NCT01884402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01884402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational,Post-authorization Prospective Study to Develop and Validate a Prognostic Tool for Optimizing Therapy in Patients With Hepatitis C Virus (HCV) Genotype 1 and 4.
Lead sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase
Observational
Overall status
Completed
Start date
October 31, 2010
Completion date
August 31, 2014
Enrollment
770 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic